Sangamo Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $18,306 | $6,437 | $7,551 | $49,412 |
Gross Profit | 18,306 | 6,437 | 7,551 | 47,285 |
EBITDA | -18,062 | -27,704 | -23,855 | 12,758 |
EBIT | -19,959 | -29,628 | -25,990 | 10,631 |
Net Income | -19,986 | -30,597 | -23,396 | 10,672 |
Net Change In Cash | 18,306 | 6,437 | 7,551 | 49,412 |
Free Cash Flow | -18,182 | -26,149 | -3,503 | 11,644 |
Cash | 38,344 | 25,180 | 41,918 | 39,201 |
Basic Shares | 256,950 | 220,269 | 210,185 | 214,325 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $57,800 | $176,232 | $111,299 | $110,701 |
Gross Profit | 57,800 | 154,040 | 111,299 | 110,701 |
EBITDA | -89,087 | -240,711 | -180,719 | -165,699 |
EBIT | -98,448 | -262,903 | -201,281 | -183,337 |
Net Income | -97,941 | -257,831 | -192,278 | -178,297 |
Net Change In Cash | 57,800 | 176,232 | 111,299 | 110,701 |
Cost of Revenue | -79,682 | 47,806 | ||
Free Cash Flow | -67,406 | -245,997 | -243,798 | -256,529 |
Cash | 41,918 | 45,204 | 100,444 | 178,872 |
Basic Shares | 201,699 | 174,444 | 154,345 | 144,568 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.08 |
2025-03-31 | -$0.14 |
2024-12-31 | -$0.11 |
